Inalossin (Nitric Oxide)

Nitric oxide released from Inalossin activates soluble guanylate cyclase in pulmonary vascular smooth‑muscle cells, raising cyclic GMP levels. Elevated cGMP causes smooth‑muscle relaxation, leading to selective dilation of pulmonary vessels without significant systemic vasodilation.

The specific dose and duration of Inalossin therapy are determined by the prescribing clinician based on the patient’s condition, weight, and response. Dosing regimens are individualized and should follow institutional protocols and the prescriber’s instructions.

Safety data for Inalossin in pregnancy and lactation are limited. The potential benefits must be weighed against unknown risks, and use is generally reserved for situations where no safer alternative exists and the therapeutic advantage is clear.

To order Inalossin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Inalossin delivers nitric oxide directly to the lungs, offering rapid and selective pulmonary vasodilation with minimal systemic effects. Compared with systemic agents such as prostacyclin analogues, inhaled nitric oxide provides a quicker onset and easier titration, but requires specialized delivery equipment and careful monitoring for methemoglobinemia.

Inalossin cylinders should be stored at ambient temperature, kept in their original packaging, and protected from heat and direct sunlight. Ensure cylinders are secured upright, check for leaks before use, and follow local regulations for handling compressed gases.

Inalossin is administered via a calibrated inhalation delivery system that mixes the gas with the patient’s ventilatory circuit. The prescribed flow rate is set on the device, and continuous monitoring of oxygenation, hemodynamics and methemoglobin levels is performed throughout therapy.

The most serious risks include methemoglobinemia, which can impair oxygen delivery, and rebound pulmonary hypertension if the gas is stopped abruptly. Severe hypotension and bronchospasm are also possible and require immediate medical attention.

Inalossin should be avoided in patients with known severe anemia, existing methemoglobinemia, or hypersensitivity to nitric oxide. It is also contraindicated when appropriate delivery equipment cannot be guaranteed or when the clinical setting cannot support the required monitoring.